דנול 200 ישראל - עברית - Ministry of Health

דנול 200

sanofi - aventis israel ltd - danazol 200 mg - capsules - danazol - treatment of endometriosis amenable to hormonal management, hereditary angioedema.

קסטרל 2.5 מ"ג ישראל - עברית - Ministry of Health

קסטרל 2.5 מ"ג

sanofi - aventis israel ltd - alfuzosin hydrochloride 2.5 mg - tablets - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, notably when surgery has to be delayed for whaterver reason and during episodes of severe symptoms of adenoma, especially in elderly patients.

קסטרל 5 מג SR ישראל - עברית - Ministry of Health

קסטרל 5 מג sr

sanofi israel ltd - alfuzosin hydrochloride - טבליות עם שחרור מושהה - alfuzosin hydrochloride 5 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy, particularly if surgery has to be delayed for some reason

קסטרל  10 מג XL ישראל - עברית - Ministry of Health

קסטרל 10 מג xl

sanofi israel ltd - alfuzosin hydrochloride - טבליות בשחרור ממושך - alfuzosin hydrochloride 10 mg - alfuzosin - alfuzosin - treatment of certain functional symptoms of benign prostatic hypertrophy particularly if surgery has to be delayed for some reason. adjuvant treatment to a catheter in acute urinary retention related to benign prostatic hypertrophy.

טריויד ישראל - עברית - Ministry of Health

טריויד

sanofi - aventis israel ltd - ofloxacin 200 mg - film coated tablets - ofloxacin - for the treatment of bacterial infections if these are due to ofloxacin sensitive pathogens.

טריויד 200 מ"ג תמיסה לאינפוזיה תוך ורידית ישראל - עברית - Ministry of Health

טריויד 200 מ"ג תמיסה לאינפוזיה תוך ורידית

sanofi - aventis israel ltd - ofloxacin 2 mg/ml - solution for infusion - ofloxacin - infections of kidney, urinarty tract, genital organs, respiratory tract, chronic and recurrent ear, nose and throat, skin and soft tissues, bones and joints, bacterial enteritis, abdominal cavity, including pelvis minor and septicemia caused by ofloxacin sensitive microorganisms. prevention of infections in patients with a signifcant reduction of resistance to infections,

טאבניק  500 מג תמיסה לאינפוזיה תוך ורידית ישראל - עברית - Ministry of Health

טאבניק 500 מג תמיסה לאינפוזיה תוך ורידית

sanofi - aventis israel ltd - levofloxacin as hemihydrate - תמיסה לאינפוזיה - levofloxacin as hemihydrate 5 mg/ml - levofloxacin - levofloxacin - in adults for whom intravenous therapy is considered to be appropriate, tavanic solution for infusion is indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: community- acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.

טאבניק טבליות 500 מג ישראל - עברית - Ministry of Health

טאבניק טבליות 500 מג

sanofi israel ltd - levofloxacin as hemihydrate - טבליות מצופות פילם - levofloxacin as hemihydrate 500 mg - levofloxacin - levofloxacin - in adults with infections of mild to moderate severity tavanic tablets are indicated for the treatment of the following infections when due to levofloxacin - susceptible micro-organisms: acute sinusitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia, complicated urinary tract infections including pyelonephritis, skin and soft tissue infections.

טארגוציד 200 מג ישראל - עברית - Ministry of Health

טארגוציד 200 מג

sanofi - aventis israel ltd - teicoplanin - אבקה להכנת תמיסה לזריקה - teicoplanin 200 mg - teicoplanin - teicoplanin - for treatment of potentially serious gram-positive infections including those which cannot be treated with other antimicrobial drugs e.g.penicillins and cephalosporins.

מנקטרה ישראל - עברית - Ministry of Health

מנקטרה

sanofi israel ltd - meningococcal vaccines group a; meningococcal vaccines group c; meningococcal vaccines group w; meningococcal vaccines group y - תמיסה להזרקה - meningococcal vaccines group c 4 mcg / 0.5 ml; meningococcal vaccines group y 4 mcg / 0.5 ml; meningococcal vaccines group w 4 mcg / 0.5 ml; meningococcal vaccines group a 4 mcg / 0.5 ml - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - active immunization of individuals 9 mouths through 55 years of age for the prevention of invasive meningococcal disease caused by n meningitidis serogroups a, c, y and w-135.